Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1244-1249
Published online before print March 3, 2005, doi: 10.1161/01.ATV.0000161420.55482.ef
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
25/6/1244    most recent
01.ATV.0000161420.55482.efv2
01.ATV.0000161420.55482.efv1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bavendiek, U.
Right arrow Articles by Schönbeck, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bavendiek, U.
Right arrow Articles by Schönbeck, U.
Related Collections
Right arrow Animal models of human disease
Right arrow Pathophysiology
Right arrow Genetically altered mice
Right arrow Growth factors/cytokines
Right arrow Mechanism of atherosclerosis/growth factors
Right arrowRelated Article
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1244.)
© 2005 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Atherogenesis in Mice Does Not Require CD40 Ligand From Bone Marrow–Derived Cells

Udo Bavendiek; Andreas Zirlik; Samantha LaClair; Lindsey MacFarlane; Peter Libby; Uwe Schönbeck

From Donald W. Reynolds Cardiovascular Clinical Research Center (U.B., A.Z., S.L., L.M., P.L., U.S.), Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; and Cardiology & Angiology (U.B.), Hannover Medical School, Germany. Current affiliation for Uwe Schönbeck: Boehringer Ingelheim Pharmaceutical Inc, Ridgefield, Conn.

Correspondence to Peter Libby, MD, Brigham and Women’s Hospital, 77 Avenue Louis Pasteur, NRB 741, Boston, MA 02115. E-mail plibby{at}rics.bwh.harvard.edu

Objective— Recent research suggests a central role for CD40 ligand (CD40L) in atherogenesis. However, the relevant cellular source of this proinflammatory cytokine remains unknown. To test the hypothesis that CD40L expressed on hematopoietic cell types (eg, macrophages, lymphocytes, platelets) is crucial to atherogenesis, we performed bone marrow reconstitution experiments using low-density receptor-deficient (ldlr–/–) and ldlr–/–/cd40l–/– compound-mutant mice.

Methods and Results— As expected, systemic lack of CD40L in hypercholesterolemic ldlr–/– mice significantly reduced the development of atherosclerotic lesions in the aortic arch, aortic root, and abdominal aorta compared with ldlr–/– mice. Furthermore, atheromata in ldlr–/–/cd40l–/– mice showed reduced accumulation of macrophages and lipids and increased content in smooth muscle cells and collagen compared with ldlr–/– mice. Surprisingly, reconstitution of irradiated ldlr–/– mice with ldlr–/–/cd40l–/– bone marrow did not affect the size or composition of atherosclerotic lesions in the root or arch of hypercholesterolemic ldlr–/– mice. Moreover, lipid deposition in the abdominal aorta diminished only marginally compared with mouse aortas reconstituted with ldlr–/– bone marrow.

Conclusions— These experiments demonstrate that CD40L modulates atherogenesis, at least in mice, primarily by its expression on nonhematopoietic cell types rather than monocytes, T lymphocytes, or platelets, a surprising finding with important pathophysiologic and therapeutic implications.

Although previous studies established CD40L as a mediator of atherogenesis, its relevant cellular source remains unknown. The present study demonstrates that CD40L modulates atherogenesis in mice, primarily by its expression on nonhematopoietic cell types in bone marrow chimeras. This surprising finding has important pathophysiologic and therapeutic implications.


Key Words: atherosclerosis • bone-marrow reconstitution • CD40 ligand • low-density lipoprotein receptor–deficient mice


Related Article:

CD40 Ligand: Not Bad to the Bone (Marrow), After All
Olujimi A. Ajijola, Pascal J. Goldschmidt-Clermont, and Lisa L. Satterwhite
Arterioscler. Thromb. Vasc. Biol. 2005 25: 1088-1090. [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Lipid Res.Home page
S. J. Peterson, G. Drummond, D. H. Kim, M. Li, A. L. Kruger, S. Ikehara, and N. G. Abraham
L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice
J. Lipid Res., August 1, 2008; 49(8): 1658 - 1669.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
D. H. Kim, A. P. Burgess, M. Li, P. L. Tsenovoy, F. Addabbo, J. A. McClung, N. Puri, and N. G. Abraham
Heme Oxygenase-Mediated Increases in Adiponectin Decrease Fat Content and Inflammatory Cytokines Tumor Necrosis Factor-{alpha} and Interleukin-6 in Zucker Rats and Reduce Adipogenesis in Human Mesenchymal Stem Cells
J. Pharmacol. Exp. Ther., June 1, 2008; 325(3): 833 - 840.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. Schneider, G. K. Sukhova, M. Aikawa, J. Canner, N. Gerdes, S.-M. T. Tang, G.-P. Shi, S. S. Apte, and P. Libby
Matrix Metalloproteinase-14 Deficiency in Bone Marrow-Derived Cells Promotes Collagen Accumulation in Mouse Atherosclerotic Plaques
Circulation, February 19, 2008; 117(7): 931 - 939.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
K. Jagavelu, U. J.F. Tietge, M. Gaestel, H. Drexler, B. Schieffer, and U. Bavendiek
Systemic Deficiency of the MAP Kinase Activated Protein Kinase 2 Reduces Atherosclerosis in Hypercholesterolemic Mice
Circ. Res., November 26, 2007; 101(11): 1104 - 1112.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
M. Luchtefeld, H. Schunkert, M. Stoll, T. Selle, R. Lorier, K. Grote, C. Sagebiel, K. Jagavelu, U. J.F. Tietge, U. Assmus, et al.
Signal transducer of inflammation gp130 modulates atherosclerosis in mice and man
J. Exp. Med., August 6, 2007; 204(8): 1935 - 1944.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. Zirlik, U. Bavendiek, P. Libby, L. MacFarlane, N. Gerdes, J. Jagielska, S. Ernst, M. Aikawa, H. Nakano, E. Tsitsikov, et al.
TRAF-1, -2, -3, -5, and -6 Are Induced in Atherosclerotic Plaques and Differentially Mediate Proinflammatory Functions of CD40L in Endothelial Cells
Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1101 - 1107.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Zirlik, C. Maier, N. Gerdes, L. MacFarlane, J. Soosairajah, U. Bavendiek, I. Ahrens, S. Ernst, N. Bassler, A. Missiou, et al.
CD40 Ligand Mediates Inflammation Independently of CD40 by Interaction With Mac-1
Circulation, March 27, 2007; 115(12): 1571 - 1580.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
A. Tedgui and Z. Mallat
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Physiol Rev, April 1, 2006; 86(2): 515 - 581.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
O. A. Ajijola, P. J. Goldschmidt-Clermont, and L. L. Satterwhite
CD40 Ligand: Not Bad to the Bone (Marrow), After All
Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1088 - 1090.
[Full Text] [PDF]